Assessment of Drug Activity and Proliferation Ex Vivo for Prediction of Outcome in Aggressive Non-Hodgkin's Lymphomas

Author： Ericsson Suzanne M. Rehn   Larsson Rolf L.   Nygren H. Peter   Sundström Christer   Glimelius Bengt L.G.  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.41, Iss.1, 2002-02, pp. : 36-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Pixantrone: a promising drug in the treatment of non-Hodgkin lymphomas

By El-Helw Loaie M   Hancock Barry W  

Future Oncology, Vol. 5, Iss. 4, 2009-05 ,pp. : 445-453

Future Medicine

Access to resources Recommend Favorite

PF-04691502, a dual PI3K/mTOR inhibitor has potent pre-clinical activity by inducing apoptosis and G1 cell cycle arrest in aggressive B-cell non-Hodgkin lymphomas

By            

International Journal of Oncology, Vol. 48, Iss. 1, 2016-01 ,pp. : 253-260

Spandidos Publications

Access to resources Recommend Favorite

The Follicular Non-Hodgkin's Lymphomas--I. The Possibility of Cure

By Denham J.W.   Denham E.   Dear K.B.   Hudson G.V.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 470-479

Elsevier

Access to resources Recommend Favorite

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP

By Dincol Dilek   Buyukcelik Abdullah   Dogan Mutlu   Akbulut Hakan   Samur Mustafa   Demirkazik Ahmet   Senler Filiz   Onur Handan   Icli Fikri  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 942-945

Humana Press, Inc

Access to resources Recommend Favorite

The Follicular Non-Hodgkin's Lymphomas--II. Prognostic Factors: What do They Mean?

By Denham J.W.   Denham E.   Dear K.B.   Hudson G.V.  

European Journal of Cancer, Vol. 32, Iss. 3, 1996-03 ,pp. : 480-490

Elsevier

Access to resources Recommend Favorite